Back to Report Store Home

Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation

  • Published: Jul-2015
  • Report Code: GBIHC364MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Innovation Trends in Product Approvals, 1987–2013

Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013

Figure 3: Relative Survival Rates for the Top 20 Cancers by Site, 2014

Figure 4: Molecule Types and Molecular Targets of Marketed Products for Oncology, 2015

Figure 5: Molecular Targets of Versatile Marketed Product for Oncology, 2015

Figure 6: Summary of Five-Year Survival Rate, Incidence and Mortality by Site, 2012

Figure 7: Pipeline Products by Therapy Area and Pipeline Oncology Products by Tumor Site, 2015

Figure 8: Developmental Pipeline Overview

Figure 9: Developmental Pipeline Overview by Molecular Target

Figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2015

Figure 11: First-in-Class Pipeline by Therapy Area and Site, 2015

Figure 12: Summary of Incidence, Mortality, Mortality Rates and Pipeline Activity by Tumor Site, 2015

Figure 13: Overview of First-in-Class Oncology Products, 2015

Figure 14: Overview of First-in-Class Oncology Products, 2015

Figure 15: Versatility of First-in-Class Oncology Pipeline Products

Figure 16: Versatility of First-in-Class Oncology Pipeline Products, as Inferred by Molecular Target

Figure 17: Versatility of First-in-Class Oncology Pipeline Products and Potential Additional Indications

Figure 18: Overview of Highly Versatile First-in-Class Pipeline Oncology Products, 2015

Figure 19: Overview of Highly Versatile First-in-Class Pipeline Oncology Products by Molecular Target, 2015

Figure 20: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets

Figure 21: Versatile First-in-Class Products in Oncology Pipeline, Part 1, 2015

Figure 22: Versatile First-in-Class Products in Oncology Pipeline, Part 2, 2015

Figure 23: Versatile First-in-Class Products in Oncology Pipeline, Part 3, 2015

Figure 24: Versatile First-in-Class Products in Oncology Pipeline, Part 4, 2015

Figure 25: Signaling Networks of Functional Families in Oncology, Part 1

Figure 26: Signaling Networks of Functional Families in Oncology, Part 2

Figure 27: Versatile First-in-Class Molecular Target Analysis Matrix, Part 1

Figure 28: Versatile First-in-Class Molecular Target Analysis Matrix, Part 2

Figure 29: Versatile First-in-Class Molecular Target Analysis Matrix, Part 3

Figure 30: Pipeline Programs Targeting Fibroblast Growth Factor Receptor-3

Figure 31: Pipeline Programs Targeting Fibroblast Growth Factor Receptor-4

Figure 32: Pipeline Programs Targeting Human Epidermal Growth Factor Receptor-3

Figure 33: Pipeline Programs Targeting Human Epidermal Growth Factor Receptor-4

Figure 34: Pipeline Programs Targeting Phosphoinositide 3-Kinase Alpha

Figure 35: Pipeline Programs Targeting Akt-1

Figure 36: Pipeline Programs Targeting Akt-2

Figure 37: Pipeline Programs Targeting Akt-3

Figure 38: Pipeline Programs Targeting Telomerase Reverse Transcriptase

Figure 39: Pipeline Programs Targeting Heat Shock Protein 90

Figure 40: Pipeline Programs Targeting Focal Adhesion Kinase

Figure 41: Pipeline Programs Targeting DNA-Dependent Protein Kinase

Figure 42: Pipeline Program Targeting Programmed Death Ligand-1

Figure 43: Industry-Wide Deals by Stage of Development, 2006–2014

Figure 44: Industry Licensing Deal Values by Stage of Development ($m), 2006–2014

Figure 45: Licensing Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2014

Figure 46: Regional Network of Licensing Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2015

Figure 47: Licensing Deals for Versatile Pipeline Oncology First-in-Class Products by Molecule Type, 2006–2015

Figure 48: Licensing Deals for Versatile Pipeline Oncology First-in-Class Products by Molecular Target, 2006–2015

Figure 49: Licensing Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2015, Part 1

Figure 50: Licensing Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2015, Part 2

Figure 51: Co-development Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2014

Figure 52: Regional Network of Co-development Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2015

Figure 53: Co-development Deals for Versatile Pipeline Oncology First-in-Class Products by Molecule Type, 2006–2015

Figure 54: Co-development Deals for Versatile Pipeline Oncology First-in-Class Products by Molecular Target, 2006–2015

Figure 55: Co-development Deals for Versatile Pipeline Oncology First-in-Class Products, 2006–2015

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards